Key Takeaways:
WuXi Biologics (Cayman) Inc. (2269.HK) announced a program to repurchase up to US$400 million of its own shares, signaling management's confidence in the company's valuation.
"The current trading price of the Shares does not reflect their intrinsic value or the actual business prospects of the Company," the company said in a statement Tuesday.
The US$400 million buyback authorization represents approximately 2.3% of Wuxi Biologics' current market capitalization of about HK$133 billion. The company stated the repurchases will be conducted "from time to time" on the open market and are covered under its existing mandate to buy back up to 407 million shares, or 10% of its issued stock.
The move follows a 4.1% year-to-date increase in the company's share price, which closed at HK$32.72 on Friday. The buyback is expected to support the stock by reducing the number of outstanding shares and potentially increasing earnings per share.
Wuxi Biologics, a major contract research, development, and manufacturing organization (CRDMO), provides end-to-end services for the global pharmaceutical industry. The decision to repurchase shares aims to "demonstrate the company's confidence in its own business outlook and prospects," according to the filing.
The share repurchase program provides a clear signal to investors that the board considers the stock undervalued. Investors will be watching the company's execution of the buyback and its impact on earnings per share moving forward.
This article is for informational purposes only and does not constitute investment advice.
